ArticleCancer cell international2026
FAK inhibitor suppresses ovarian cancer growth by inhibiting tumor angiogenesis.
Article in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundOvarian cancer, the second deadliest gynecological malignancy, necessitates the identification of novel therapeutic targets. Focal adhesion kinase (FAK), a non-receptor tyrosine kinase, has emerged as a promising target for ovarian cancer treatment owing to its diverse regulatory roles. While existing research has demonstrated FAK's role in tumor progression and angiogenesis, substantial knowledge gaps remain concerning the precise mechanisms through which FAK inhibitors hinder tumorigenesis and their specific roles in anti-angiogenic processes.
methodsThis study utilized bioinformatics analysis to examine FAK expression in ovarian cancer, with validation performed using clinical samples from platinum-sensitive and platinum-resistant patients. The anti-tumor effects of FAK inhibitors were investigated through in vitro and in vivo experiments. Human induced pluripotent stem cells (hiPSCs) were differentiated into endothelial cells to facilitate vascular research. Pharmacological inhibition and genetic knockdown techniques were employed to study FAK's role in angiogenesis, followed by functional assays to analyze specific angiogenesis processes.
resultsBioinformatics analysis identified increased FAK expression in ovarian cancer tissues, which was significantly associated with poor prognosis. Clinical specimens confirmed higher levels of total FAK and pY397 FAK in platinum-resistant cancers compared to sensitive counterparts. In vivo experiments, including laser speckle contrast imaging and CD31 immunofluorescence, demonstrated that FAK inhibitors suppress tumor angiogenesis. Both pharmacological and genetic approaches revealed a pivotal regulatory function of FAK in angiogenesis. FAK inhibition appeared particularly effective in disrupting endothelial sprouting processes across the tested models.
conclusionsThe results provide compelling experimental evidence supporting FAK inhibitors as potential targeted therapeutic agents for ovarian cancer. Our findings suggest that the anti-tumor effects of FAK inhibitors are closely associated with the suppression of tumor angiogenesis, which may be attributed to the potent inhibitory impact of FAK blockade on endothelial sprouting. This reveals a distinct mechanism of action that differs from traditional cytotoxic agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.